EUVIMEDEUVIMED entdecken
Open Access

NPP-669, a prodrug of cidofovir, is highly efficacious against human adenovirus infection in the permissive Syrian hamster model

Ann E Tollefson, Anna B Cline-Smith, Jacqueline F Spencer, Dawn M Reyna, Elke Lipka, Karoly Toth iD

Antimicrobial Agents and Chemotherapy · 2024

DOI: 10.1128/aac.00489-24 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2024. Verfasst von Ann E Tollefson und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Microbiology and Immunology, Saint Louis University School of Medicine, St. Louis, Missouri, USA. Hauptthemen laut MEDLINE: Antiviral Agents, Prodrugs, Cidofovir, Mesocricetus. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Human adenoviruses can cause serious, disseminated infections in immunocompromised patients. For pediatric allogeneic stem cell transplant patients, the case fatality rate can reach 80%. Still, there is no available antiviral drug that is specifically approved by the Food and Drug Administration for the treatment of adenovirus infections. To fill this pressing medical need, we have developed NPP-669, a prodrug of cidofovir with broad activity against double-stranded DNA viruses, including adenoviruses. Here, we report on the in vivo anti-adenoviral efficacy of NPP-669. Using the immunosuppressed Syrian hamster as the model, we show that NPP-669 is highly efficacious when dosed orally at 1 mg/kg and 3 mg/kg. In a delayed administration experiment, NPP-669 was more effective than brincidofovir, a similar compound that reached Phase III clinical trials. Furthermore, parenteral administration of NPP-669 increased its efficacy approximately 10-fold compared to oral dosing without apparent toxicity, suggesting that this route may be preferable in a hospital setting. Based on these findings, we believe that NPP-669 is a promising new compound that needs to be further investigated.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antiviral AgentsProdrugsCidofovirMesocricetusOrganophosphonatesCytosineAnimalsHumansAdenoviruses, HumanAdenovirus Infections, HumanDisease Models, AnimalCricetinaeAdministration, Oral

Stichwörter der Autor:innen

adenovirusanimal modelantiviralin vivoprodrug

Substanzen

Antiviral AgentsProdrugsCidofovirOrganophosphonatesCytosinebrincidofovir

Autor:innen und Institutionen

  • Department of Molecular Microbiology and Immunology, Saint Louis University School of Medicine, St. Louis, Missouri, USA.
  • TSRL, Inc., Ann Arbor, Michigan, USA.

ORCID-Profile: Karoly Toth

Förderung

  • NIAID NIH HHS
  • HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID)

Zitieren

APA

Tollefson, A. E., Cline-Smith, A. B., Spencer, J. F., Reyna, D. M., Lipka, E., & Toth, K. (2024). NPP-669, a prodrug of cidofovir, is highly efficacious against human adenovirus infection in the permissive Syrian hamster model. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.00489-24

Vancouver

Tollefson AE, Cline-Smith AB, Spencer JF, Reyna DM, Lipka E, Toth K. NPP-669, a prodrug of cidofovir, is highly efficacious against human adenovirus infection in the permissive Syrian hamster model. Antimicrobial Agents and Chemotherapy. 2024. doi:10.1128/aac.00489-24

BibTeX
@article{Tollefson2024,
  author = {Tollefson, Ann E and Cline-Smith, Anna B and Spencer, Jacqueline F and Reyna, Dawn M and Lipka, Elke and Toth, Karoly},
  title = {NPP-669, a prodrug of cidofovir, is highly efficacious against human adenovirus infection in the permissive Syrian hamster model},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2024},
  doi = {10.1128/aac.00489-24}
}
Kostenlos starten →